Methods and compositions for treating skin disease with recombinant microorganisms
AssigneeAzitra Inc
InventorTravis Michael Whitfill
Life of this patent
Estimating the term…
Abstract
The present invention provides isolated plasmids, recombinant microorganisms, kits, and methods for the treatment of inflammatory skin disease.
Claims13
A recombinant microorganism capable of secreting a filaggrin polypeptide, wherein the microorganism is selected from the group consisting of Bifidobacterium, Brevibacterium, Propionibacterium, Lactococcus, Streptococcus, Staphylococcus, Lactobacillus, Enterococcus, Pediococcus, Leuconostoc, or Oenococcus, wherein the recombinant microorganism comprises an expression vector comprising a first coding sequence comprising a gene capable of expressing the polypeptide and a second coding sequence comprising a gene capable of expressing a cell penetrating peptide, wherein the filaggrin polypeptide comprises an amino acid sequence at least 95% identical to SEQ ID NO:15.
A method for producing a live biotherapeutic composition, the method comprising:
- (a) transfecting a cell with (i) a first coding sequence comprising a nucleic acid sequence capable of expressing a filaggrin polypeptide, and (ii) a second coding sequence comprising a nucleic acid sequence capable of expressing a cell penetrating peptide, wherein the cell is a bacterial cell selected from the group consisting of Bifidobacterium, Brevibacterium, Propionibacterium, Lactococcus, Streptococcus, Staphylococcus, Lactobacillus, Enterococcus, Pediococcus, Leuconostoc, or Oenococcus, wherein the filaggrin polypeptide comprises an amino acid sequence at least 95% identical to SEQ ID NO:
- 15;
- and
- (b) allowing the transfected cell to produce a therapeutic polypeptide fusion protein;
- and
- (c) obtaining the live biotherapeutic composition.
A live biotherapeutic composition comprising a recombinant microorganism wherein the recombinant microorganism comprises
- (i) a first coding sequence comprising a nucleic acid sequence capable of expressing a therapeutic polypeptide;
- (ii) a second coding sequence comprising a nucleic acid sequence capable of expressing a cell penetrating peptide;
- (iii) a third coding sequence comprising a nucleic acid sequence capable of expressing an export signal;
- and
- (iv) a promoter operably linked to the first coding sequence, the second coding sequence and the third coding sequence;
- wherein the first coding sequence, second coding sequence and first coding sequence is capable of expressing a filaggrin fusion product, or variant thereof.
Dependencies are inferred from the claim text.